静脉注射人免疫球蛋白可致半乳甘露聚糖试验假阳性
该研究评估静脉注射人免疫球蛋白(IVIG)后半乳甘露聚糖酶免疫试验(GM-EIA)的假阳性率及相关因素。所有稀释和纯IVIG样本GM试验均阳性,热处后GMI显著升高。48例IVIG后1周内GM-EIA阳性患者中22例(45.8%)为假阳性,假阳性组GMI转阴更快,真阳性组更易连续阳性。
要点
- IVIG本身可导致GM-EIA假阳性,用药后阳性结果需谨慎解读。
- IVIG后1周内GM-EIA阳性者中假阳性率可达45.8%。
- 假阳性者GMI多在IVIG后14-18天内转阴,动态监测有助鉴别。
核心结论
- IVIG治疗可能产生假阳性GM-EIA结果,接受IVIG患者GMI阳性应谨慎解读。
研究设计与样本
- 对稀释和纯IVIG样本(含或不含热处理)进行标准GM-EIA检测。
- 纳入IVIG给药1周内至少有一次GM-EIA结果的成人患者,排除IVIG前1年内有侵袭性曲霉病者。
- 比较假阳性和真阳性患者的临床特征及GMI动态。
主要发现
- 所有稀释和纯IVIG样本GM试验均阳性,热处理可导致GMI显著升高。
- 48例IVIG后1周内GM-EIA阳性患者中,22例(45.8%)为假阳性。
- IVIG结束后假阳性组全部GMI下降,真阳性组仅26例中18例(69.2%)下降。
- IVIG后7、14、18天,假阳性组GMI转阴分别为7/15(46.7%)、18/20(90%)、22/22(100%),真阳性组分别为6/24(25%)、14/24(58.3%)、16/26(61.5%)。
- 真阳性组更可能在IVIG后出现两次或以上连续GMI阳性(调整OR 9.01,95%CI 1.99-40.9)。
临床怎么用
- 对接受IVIG的患者,GM-EIA阳性结果应结合临床和影像学谨慎判断。
- 动态监测GMI有助于区分假阳性和真阳性,连续阳性更支持真阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Evidence of false-positive galactomannan enzyme immunoassay (GM-EIA) results associated with intravenous immunoglobulin (IVIG) administration is scarce. Here, we aimed to determine the false-positive rate of GM-EIA after IVIG administration and to identify the related factors. METHODS: Standard GM-EIA was performed using diluted and pure human IVIG samples with and without heat treatment. We also included adult patients who had at least one GM-EIA result within 1 week of IVIG administration for analysis. Those who had prior invasive aspergillosis within 1 year before IVIG therapy were excluded. The clinical characteristics and galactomannan index (GMI) kinetics between patients with false-positive and true-positive GMI were compared. RESULTS: All diluted and pure IVIG samples tested positive for GM. Heat treatment resulted in the considerable elevation of GMI. Of 48 patients with positive GM-EIA results within 1 week of IVIG administration, 22 (45.8%) were considered to have false-positive antigenaemia (false-positive group, FPG). After the completion of IVIG administration, a decline in GMI was observed in all FPG patients but in only 18 out of 26 patients (69.2%) with true-positive results (true-positive group, TPG). By 7, 14, and 18 days of IVIG administration, GMI reverted to negative values in 7/15 (46.7%), 18/20 (90%) and 22/22 (100%) FPG patients, respectively, and 6/24 (25%), 14/24 (58.3%), and 16/26 (61.5%) of TPG patients, respectively. The TPG was more likely to have two or more consecutively positive GMIs after IVIG administration than the FPG (adjusted odds ratio, 9.01; 95% confidence interval, 1.99-40.9). CONCLUSIONS: IVIG treatment may produce false-positive GM-EIA results. A positive GMI among patients receiving human IVIG should be interpreted with caution.
引用
- Liu WD, Lin SW, Shih MC, et al. False-positive Aspergillus galactomannan immunoassays associated with intravenous human immunoglobulin administration. Clin Microbiol Infect. 2020. PMID: 32061794. doi:10.1016/j.cmi.2020.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。